Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Pyridoxal. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.60 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.60 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.60 |
| ▸ | GAA known ✓ | P10253 | 3/20 | 0.50 |
| ▸ | TRIM24 | O15164 | 1/20 | 1.00 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.97 |
| ▸ | LMNA | P02545 | 6/20 | 0.97 |
| ▸ | HPGD | P15428 | 5/20 | 0.97 |
| ▸ | MEN1 | O00255 | 2/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.97 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.97 |
| ▸ | PDXK | O00764 | 2/20 | 0.68 |
| ▸ | ACP1 | P24666 | 1/20 | 0.60 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.60 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 5/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridoxal SCHEMBL27840086 | 1.00 | TRIM24 (1.00) | TRIM24TRIM33KDM4EALDH1A1LMNA | |
| Pyridoxal SCHEMBL29906 | 0.98 | KDM4E (1.00) | TRIM24TRIM33KDM4EALDH1A1LMNA | |
| Pyridoxal SCHEMBL361981 | 0.97 | TRIM24 (0.94) | TRIM24TRIM33KDM4EALDH1A1LMNA | |
| Pyridoxal SCHEMBL4668019 | 0.97 | KDM4E (0.97) | TRIM24TRIM33KDM4EALDH1A1LMNA | |
| Pyridoxal SCHEMBL30963032 | 0.97 | KDM4E (0.97) | TRIM24TRIM33KDM4EALDH1A1LMNA | |
| Pyridoxal SCHEMBL5416120 | 0.97 | KDM4E (0.97) | TRIM24TRIM33KDM4EALDH1A1LMNA | |
| Pyridoxal SCHEMBL8533734 | 0.97 | KDM4E (0.97) | TRIM24TRIM33KDM4EALDH1A1LMNA | |
| Pyridoxal SCHEMBL2527773 | 0.97 | KDM4E (0.97) | TRIM24TRIM33KDM4EALDH1A1LMNA | |
| Pyridoxal SCHEMBL29389313 | 0.97 | KDM4E (0.97) | TRIM24TRIM33KDM4EALDH1A1LMNA | |
| Pyridoxal SCHEMBL28090030 | 0.97 | KDM4E (0.97) | TRIM24TRIM33KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3107 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121379932-B | Culture medium for high-density serum-free suspension culture of BHK-21 cells and application thereof | Zhongsheng tianxinhe (Wuxi) Biotechnology Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| US-20260085292-A1 | MINIMAL ESSENTIAL MEDIA FOR THE CULTURE OF HUMAN INDUCED PLURIPOTENT STEM CELLS | UNIV NORTHWESTERN (US) | 2026-03-26 | — | — | US | claimed |
| EP-4469560-B1 | AN IMPROVED CELL CULTURE MEDIUM FOR CRUSTACEAN CELLS | UNIV GENT (BE) | 2026-03-11 | — | — | EP | claimed |
| CN-121575053-A | Propionic acid culture medium and propionibacterium fermentation method based on propionic acid culture medium | 华慧海洋多糖生物技术(深圳)有限公司 | 2026-02-27 | — | — | CN | claimed |
| US-12534706-B2 | Method for maturation of retinal tissue containing continuous epithelium | RIKEN (JP) | 2026-01-27 | — | — | US | claimed |
| EP-4017496-B1 | FORMULATIONS FOR USE IN THE PREVENTION AND/OR TREATMENT OF PERIPHERAL NEUROPATHY AND ITS ASSOCIATED DISEASES | LOH YIN SZE (SG) | 2026-01-07 | — | — | EP | claimed |
| EP-4658756-A2 | IMPROVED MICROBIAL GROWTH MEDIA | Becton, Dickinson and Company (US) | 2025-12-10 | — | — | EP | claimed |
| EP-3794005-B1 | INORGANIC SALTS OF NICOTINIC ACID MONONUCLEOTIDE AS ANTI-AGING AGENTS | Jumpstart Fertility Pty Ltd (AU) | 2025-10-22 | — | — | EP | claimed |
| US-20250243437-A1 | METHOD FOR PRODUCING AGAVE CULTURES FOR TEQUILA | PHYTO TEQ, INC. (US) | 2025-07-31 | — | — | US | claimed |
| US-20250243436-A1 | METHOD FOR PRODUCING AGAVE CULTURES FOR TEQUILA | PHYTO TEQ, INC. (US) | 2025-07-31 | — | — | US | claimed |
| WO-1996002531-A1 | WATER SOLUBLE ORALLY EFFECTIVE IRON CHELATOR | JACOBUS PHARMACEUTICAL CO., INC. (US) | 1996-02-01 | — | — | WO | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |
| US-4560655-A | FETUIN, TRANSFERRIN, ALBUMIN, CHOLESTEROL, AND PHOSPHATIDYLCHOLINE | IMMUNEX CORPORATION (US) | 1985-12-24 | — | — | US | claimed |
| US-4533637-A | REPLACING SERUM WITH CYCLODEXTRINS | AJINOMOTO CO., INC. (JP) | 1985-08-06 | — | — | US | claimed |
| EP-0019054-B1 | NUTRIENT MEDIUM AND ITS USE IN TESTING ANTIMICROBIAL AGENTS | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1982-05-05 | — | — | EP | claimed |
| US-4275154-A | Nutrient medium | HOFFMANN-LA ROCHE INC. (US) | 1981-06-23 | — | — | US | claimed |
| EP-0019054-A1 | Nutrient medium and its use in testing antimicrobial agents | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1980-11-26 | — | — | EP | claimed |
| US-4115576-A | 5-HYDROXYMETHYLCYTOSINE, A B6 VITAMIN, NICOTINAMIDE OR NICOTINIC ACID | PENN NATHAR W | 1978-09-19 | — | — | US | claimed |
| US-4048316-A | Composition for antagonizing the narcotic effects of barbiturate addiction and withdrawal effects, and for treatment of barbiturate poisoning | PENN NATHAR W | 1977-09-13 | — | — | US | claimed |
| US-3981980-A | Radiopharmaceuticals for cholescintigraphy | The Council of the Institute of Medical and Veterinary Science (AU) | 1976-09-21 | — | — | US | claimed |